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for Death
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Background and Purpose—Hematoma volume and impaired level of consciousness are the most potent predictors of
outcome after spontaneous intracerebral hemorrhage (ICH). The effect of preceding aspirin-use on outcome after ICH
is poorly investigated. We investigated short-term mortality and hematoma enlargement in subjects with ICH to find the
predictors for these outcomes.
Methods—This population-based study included all subjects with ICH during a period of 33 months in the population of
Northern Ostrobothnia, Finland. The subjects were identified, and their clinical characteristics and outcomes were
checked from hospital records or death records.
Results—Three-month mortality of the 208 identified subjects with ICH was 33%. The independent risk factors for death
were regular aspirin-use at the onset of ICH (relative risks [RR], 2.5; 95% CI, 1.3 to 4.6; P0.004), warfarin-use at the
onset of ICH (RR, 3.2; 95% CI, 1.6 to 6.1; P0.001), and ICH score higher than 2 on admission (RR, 13.8; 95% CI,
6.0 to 31.4; P0.001). Regular aspirin-use preceding the onset of ICH associated significantly with hematoma
enlargement during the first week after ICH (P0.006).
Conclusions—We observed poor short-term outcomes and increased mortality, probably attributable to rapid enlargement
of hematomas, in the subjects with ICH who had been taking regularly moderate doses of aspirin (median 250 mg)
immediately before the onset of the stroke. (Stroke. 2006;37:129-133.)
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Independent predictors of short-term mortality (30 days)after spontaneous intracerebral hemorrhage (ICH) include
the size and location of the hemorrhage, a midline shift in
head computed tomography (CT), intraventricular spread of
the hemorrhage, low Glasgow Coma Scale (GCS) score on
admission, and high blood glucose and blood pressure on
admission.1–6 Preceding medication and hematologic abnor-
malities may also predict the outcome, but their independent
roles are less clear.
Many reports have demonstrated that patients on warfarin
show a high mortality rate (52% to 68%) attributable to rapid
enlargement of their hematomas.7,8 Use of antiplatelet agents
has not been shown to exert a similar effect, but as far as we
know, only a few studies have been reported.8–10 To resolve
the role of aspirin, in particular, we investigated outcome and
hematoma enlargement in a population-based cohort of pa-
tients with ICH.
Methods
We identified all subjects with ICH between January 1993 and Septem-
ber 1995 in the population of Northern Ostrobothnia, Finland. The study
included all patients admitted into Oulu University Hospital for ICH
during this period. Oulu University Hospital is the only hospital serving
acute stroke patients in the area (population 356 026). ICH was verified
by a head CT scan on admission in all cases. We excluded patients not
living in the catchment area of the hospital and those with a brain tumor,
aneurysm, vascular malformation, hematologic malignancy, hemo-
philia, or head trauma. The fatal cases of ICH in the community during
the study period were identified from death records (Statistics Finland),
but cases without verification of ICH at autopsy or by brain imaging
were excluded. The study protocol was approved by the ethics commit-
tee of the hospital.
Information about previous diseases, blood pressure histories,
medications, and smoking were extracted from the hospital records.
Data were extracted from the forensic autopsy charts of those who
had succumbed on the scene. Cardiac complications, infection, deep
vein thrombosis, or pulmonary embolus during hospitalization were
recorded, as were also neurosurgical interventions. The time of ICH
onset was defined to be the acute onset of headache or a neurological
deficit.
The subjects were considered to be hypertensive if their blood
pressure readings preceding the index stroke had repeatedly ex-
ceeded 160/95 mm Hg, or if they were taking antihypertensive
medication. The patients were recorded as having diabetes mellitus if
they used oral hypoglycemic agents or insulin. Previous hemorrhagic
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and ischemic strokes were recorded. Cardiac disease included
myocardial infarction, coronary artery disease, heart failure, and
atrial fibrillation. Gastrointestinal bleeding and hematuria in the
patients’ history were recorded. Subjects were categorized into
current cigarette smokers and nonsmokers.
The ICH score11 was calculated on the basis of the GCS score12 on
admission, volume, supra- or infratentorial location and ventricular
extension of the hematoma, and the patient’s age. The scores were
classified into 3 categories: zero (0 points), low (1 to 2 points), and
high (3 to 6 points). The patients’ survival during the first 3 months
after the onset of ICH was checked from hospital records and death
records. Functional outcome at 3 months was assessed according to
the Glasgow Outcome Scale13 on scheduled control visits3 months
after the ICH. Those who showed good recovery at discharge were
assumed to maintain this state at 3 months, unless they had been
readmitted.
All CT scans were reanalyzed and the locations and volumes of
hematomas measured by the same neuroradiologist (J.P.) who was
blind to the medications and outcomes of the patients. Hematomas
were divided into categories based on their location. The volumes of
the hematomas were measured following previously described prin-
ciples.14 The volumes were measured on a workstation by encircling
the boundaries of each hematoma with a pointer slice by slice and
thereby determining its area. The area was multiplied by slice
thickness (5 mm in posterior fossa and 10 mm supratentorially) to
obtain the volume. The presence of intraventricular bleeding was
recorded. Possible enlargement of the hematoma was assessed in the
patients who received a second CT scan within a week after the onset
of ICH. For statistical analysis, relative enlargement (by percent) of
hematomas were calculated. A second CT scan was always obtained
if clinical deterioration occurred, except for those patients who were
already moribund on admission.
Categorical variables were compared by Fisher exact 2-tailed test
and the Pearson 2 test. Continuous variables were compared
between the groups by the Mann-Whitney U-test, Student t test, and
ANOVA. For life table analysis and the Cox proportional hazards
regression model, each patient was followed to death or until 3
months after ICH. Cumulative survival rates were estimated by the
Kaplan-Meier product-limit method, and the curves of the different
groups were compared by the log-rank test. The Cox proportional-
hazards model with a forward stepwise-regression procedure served
to determine the significance of several variables in predicting
relative risks (RR) and 95% CI for death. The following variables,
which were known at the beginning of follow-up, were analyzed:
age; sex; history of hypertension, ischemic or hemorrhagic stroke,
cardiac disease, diabetes, and cancer; ICH score; warfarin treatment;
regular aspirin-use; bleeding disorders; and current smoking. The
assumption of proportionality was checked. The test for significance
was based on changes in log (partial) likelihood. A 2-tailed proba-
bility value of 0.05 was considered to be statistically significant.
Results
We found altogether 208 subjects with a verified spon-
taneous ICH during the study period, and the crude annual
incidence rate was 21/100 000. The baseline characteristics of
the subjects are shown in Table 1. Two hundred and three
patients were admitted into our hospital, and the diagnosis
was verified by a head CT scan. Five subjects succumbed
elsewhere, and their diagnoses were verified at autopsy. The
aspirin users were significantly older than nonusers of aspi-
rin/warfarin (P0.004). History of cardiac disease (P0.01)
and ischemic stroke (P0.01) were more common in the
group of aspirin/warfarin users than in the nonuser group.
The clinical characteristics and outcomes are shown in
Table 2. On admission, aspirin users did not have larger
hematomas than nonusers of aspirin/warfarin, but warfarin
users had significantly larger hematomas than aspirin users
(P0.015) and nonusers of aspirin/warfarin (P0.012). CT
scanning was performed on the day of symptom onset in 73%
of aspirin users, 76% of warfarin users, and 70% of nonusers
of aspirin/warfarin. The groups differed significantly by
outcome at 3 months (P0.001) and bleeding into the
ventricles (P0.001), the latter finding being most frequent
in warfarin users. In the 47 patients with ICH score 2, 55%
had GCS score 3 to 4, 40% had GCS score 5 to 12, 74% had
hematoma volume 30 cm3, 89% had intraventricular and
13% had infratentorial hemorrhage, and 28% were aged 80
years.
The primary bleed was the cause of death in 17 (89%) of
the 19 fatalities in the group of aspirin users. The 2 others
died of pneumonia and pulmonary embolism. Among warfa-
rin users, the cause of death was the primary bleed in 18 cases
(95%), and 1 patient died of thrombosis of the abdominal
TABLE 1. Baseline Characteristics of 208 Subjects With Spontaneous ICH
Characteristics
No Aspirin or Warfarin
(n138)
Aspirin Users
(n44)
Warfarin Users
(n26)* Total (n208)
Men, n (%) 68 (49) 22 (50) 11 (42) 101 (49)
Mean age, y (SD) 65.6 (11.1) 71.6 (11.2) 70.0 (11.1) 67.4 (11.4)
Mean BMI, kg/m2 (SD) 27.4 (5.9) 27.4 (5.6) 26.8 (6.5) 27.3 (5.8)
Previous diseases, n (%)
Hypertension 79 (57) 29 (66) 19 (73) 127 (61)
Hypertension untreated 29 (21) 7 (16) 0 36 (17)
Cardiac disease 44 (32) 26 (59) 22 (85) 92 (44)
Ischemic stroke 12 (9) 19 (43) 11 (42) 42 (20)
Hemorrhagic stroke 14 (10) 6 (14) 0 20 (10)
Gastrointestinal bleeding 9 (7) 5 (11) 5 (19) 19 (9)
Hematuria 7 (5) 3 (7) 3 (12) 13 (6)
Cancer 15 (11) 6 (14) 2 (8) 23 (11)
Diabetes mellitus 12 (9) 8 (18) 2 (8) 22 (11)
Current smoking 15/115 (13) 5/37 (14) 3/23 (13) 23/175 (13)
*One subject in the warfarin group also was regular aspirin user.
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aorta. Thirty nonusers of aspirin/warfarin died within 3
months, the causes of death being the primary bleed in 24
cases (80%) and pneumonia, myocardial infarction, and
gastrointestinal bleeding in 3, 2, and 1 cases, respectively.
A second CT scan was available for 104 patients. Median
time interval between the baseline and the second CT scan
was 7 days (25th and 75th percentiles, 4 and 9). Regular
aspirin-use preceding the onset of ICH associated signifi-
cantly with relative hematoma growth (by percent; P0.006;
Mann-Whitney U-test). We also dichotomized hematoma
enlargement as previously reported (33%).9,15 In this anal-
ysis, the association of aspirin-use with hematoma enlargement
did not reach statistical significance, probably attributable to
the limited number of aspirin users with a second CT scan. A
nearly significant correlation between hematoma enlargement
and mortality was observed (P0.087). However, 8 aspirin
users (18%) died within 4 days after the onset of ICH without
a second CT scan. Most warfarin users had large hematomas
on admission already, and 16 (62%) of them died within the
first 4 days without a second CT scan. Because of the small
number of warfarin users with a second CT scan, the association
between warfarin-use and hematoma enlargement did not reach
statistical significance (P0.082). The 4-day mortality of non-
users of aspirin/warfarin was 11% (15 patients).
The cumulative survival rates are shown in the Figure.
Overall mortality within 3 months was 32.7%. The mortality
rates of aspirin users, warfarin users and nonusers of aspirin/
warfarin were 43.2%, 73.1% and 21.7%, respectively. The
log-rank test revealed significant differences between the
survival curves of aspirin users and nonusers of aspirin/
warfarin (P0.0048) as well as between warfarin users and
nonusers of aspirin/warfarin (P0.0001) and between aspirin
users and warfarin users (P0.0026). Univariate and multi-
variate RRs of the significant predictors of death during the
first 3 months after the onset of ICH are shown in Table 3.
The median daily dose of aspirin used was 250 mg (range,
50 to 500). There was no significant difference in the aspirin
doses of the patients who died within 3 months after their ICH
and of those who survived (P0.58). Nor were there signif-
icant differences in mean platelet count between the study
groups or between the survivors and those who died. The
mean international normalized ratio (INR) of warfarin users
on admission was 3.81.8 (range 1.5 to 7.8). The difference
between the INRs of the warfarin users who died within
the first 3 months after ICH and of the survivors was not
significant (P0.43).
Discussion
This population-based study indicated that regular aspirin use
before the onset of primary ICH was a significant indepen-
dent predictor for death within the first 3 months after the
index stroke. This is a novel finding. Other significant pre-
dictors for death were warfarin-use and a high ICH score on
admission.
We found 2-fold 3-month-mortality in aspirin users com-
pared with nonusers of aspirin/warfarin. The deaths of aspirin
TABLE 2. Clinical Characteristics and Outcome in 208 Subjects With Spontaneous ICH
Characteristics
No Aspirin or Warfarin
(n138)
Aspirin Users
(n44)
Warfarin Users
(n26) Total (n208)
Median volume of ICH, mL (25th and
75th percentiles)
20 (7, 39) 16 (6, 48) 50 (16, 112) 21 (7, 45)
Intraventricular hemorrhage (%) 54 (39) 11 (25) 18 (69) 83 (40)
Mean MAP*, mm Hg (SD) 126 (24) 127 (21) 132 (22) 127 (23)
Mean blood glucose on admission, mmol/L (SD) 8.0 (3.7) 8.9 (4.7) 9.9 (8.6) 8.4 (4.8)
Mean platelet count on admission, 103/L (SD) 264.4 (79.0) 261.8 (68.7) 247.4 (63.0) 262.0 (75.0)
Location of hematoma, n (%)
Subcortex 44 (32) 10 (23) 9 (35) 63 (30)
Basal ganglia (and combined†) 59 (43) 20 (45) 11 (42) 90 (43)
Thalamus 15 (11) 6 (14) 3 (12) 24 (12)
Cerebellum and pons 20 (14) 8 (18) 3 (12) 31 (15)
ICH Score, n (%)
0 38/132 (29) 14/43 (33) 4/24 (17) 56/199 (28)
1 to 2 69/132 (52) 20/43 (47) 7/24 (29) 96/199 (48)
2 25/132 (19) 9/43 (21) 13/24 (54) 47/199 (24)
Glasgow Outcome Scale at 3 mo, n (%)
Good recovery 39 (28) 11 (25) 2 (8) 52 (25)
Moderate disability 24 (17) 2 (5) 1 (4) 27 (13)
Severe disability or vegetative state‡ 45 (33) 12 (27) 4 (15) 61 (29)
Dead 30 (22) 19 (43) 19 (73) 68 (33)
Enlargement of hematoma§, n (%) 6/78 (8) 4/21 (19) 1/5 (20) 11/104 (11)
Mean enlargement of hematoma, % (SD) 4.8 (16.1) 12.8 (22.6) 10.6 (16.8) 6.7 (17.7)
*Mean arterial blood pressure on admission; †Extension of putaminal hematoma into thalamus and subcortical white matter;
‡Noone remained in a vegetative state; §By 33%.
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users were attributable to ICH, except in 2 cases. On admis-
sion, aspirin-related hemorrhages were of the same size as
those seen in nonusers of aspirin/warfarin. Other investigators
have also reported that the baseline hematoma size in patients
using platelet-inhibiting drugs is no greater than that in
patients not using such drugs.9 In our study, aspirin-use
significantly associated with hematoma growth, which has
been shown to be an independent factor increasing mortality
after ICH.16
We believe that the untoward effect of aspirin-use on
short-term outcome was attributable to early enlargement of
hematomas in aspirin users. However, we were unable to
prove this hypothesis because a second CT scan was available
for only 104 patients. On the other hand, mortality during the
first 4 days after the onset of ICH was higher (18%) in aspirin
users than in nonusers of aspirin/warfarin (11%), despite the
fact that aspirin users did not have larger hematomas on
admission than nonusers of aspirin/warfarin. The cause of
death in these cases may have been early hematoma growth.
Alternatively, use of aspirin may have emerged as a risk
factor for death after ICH attributable to a proxy effect of
several factors associated with its use, like patient age,
diabetes and history of cardiac disease and ischemic stroke,
although these were not solitary independent risk factors.
Previous studies have not found recent use of antiplatelet
agents to associate with an increased risk of hematoma
expansion9 or higher mortality.8 –10 However, in the 2
hospital-based studies,8,9 the most potent antiplatelet drug,
aspirin, was not distinguished from other nonsteroidal anti-
inflammatory drugs (NSAIDs). In the population-based study
by Nilsson et al,10 a nonsignificant trend for aspirin to predict
mortality may be seen after omitting warfarin users. In the
Swedish Aspirin Low-dose Trial (SALT), there was a signif-
icant increase in the risk of fatal hemorrhagic strokes among
the aspirin (75 mg/day) users.17 A plausible explanation for
the increased mortality of aspirin users would be more
frequent hematoma enlargement caused by impaired hemo-
stasis during the first few days after the onset of ICH. We
recently observed prolonged bleeding times on admission in
ICH patients who had been using aspirin, and even after the
discontinuation of aspirin, the effect of the drug on hemosta-
sis continued for a few days.18 The high 3-month mortality in
warfarin users reflects the facts that most of them showed
large hematomas on admission and no effective measure to
reverse the anticoagulant effect was used.
Hematoma volume is a potent predictor of mortality and
functional outcome.2,4,5,11 Decreased blood coagulability,19,20
increased blood pressure,8 liver disease,20 thrombocytope-
nia,20 insufficient thrombin generation,19 and elevated INR
value20 may all foster hematoma enlargement. This list may
also include insufficient platelet function induced by aspirin,
but the risk of aspirin-use should be weighed against each
individual’s need for medication and the possible risks of
alternative medications. It has been suggested that ongoing
enlargement of ICH might be detected on the basis of extrava-
sation of radiographic contrast into the hematoma after CT
angiography.21
Three-month survival of 208 subjects
with ICH according to use of aspirin or
warfarin (nonusers of aspirin/warfarin,
n138; aspirin users, n44; warfarin
users, n26).
TABLE 3. Predictors for Death Within the First 3 Months
After ICH
Variable
Univariate RR
(95 % CI)
Multivariate RR*
(95% CI)
ICH Score 2 on admission 14.5 (6.5–32.5)† 13.8 (6.0–31.4)†
Warfarin use preceding ICH 3.9 (2.1–7.2)† 3.2 (1.6–6.1)‡
Regular aspirin use preceding
ICH
2.5 (1.4–4.6)‡ 2.5 (1.3–4.6)‡
Diabetes 2.4 (1.2–4.8)§ 2.1 (0.99–4.3)
*RRs have been adjusted for age, sex, and the variables listed in the table;
†P0.001; ‡P0.01; §P0.05.
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Our findings suggest that prevention of hematoma growth
may be needed if aspirin has been used by the ICH patient. In
patients on warfarin, emergent reversal of anticoagulation
is needed as quickly as possible.7 In aspirin-associated ICH,
reversal of the antiplatelet effect of aspirin by platelet trans-
fusions could be attempted. Platelet transfusion has been
recommended in life-threatening ICH attributable to autoim-
mune thrombocytopenia.22 However, we need further studies
to prove that early hematoma growth leads to increased
mortality in aspirin users and that platelet transfusion is
efficient and safe as a preventive measure.
The strength of our study is that it was based on a defined
population. We included all patients admitted into our hos-
pital because of ICH during the study period, without selec-
tion based on, for example, the delay before CT scanning.
Because there are no other hospitals in the area admitting
acute stroke patients, and such patients are recommended to
be immediately referred to our hospital, we believe we were
able to avoid selection bias. In addition, we identified the
subjects with ICH who died during the study period without
ever reaching the hospital. Of these, we included only the
patients with ICH confirmed at autopsy. However, the strict
inclusion criteria may result in underestimation of the real
incidence rate of spontaneous ICH in the population. The lack
of systematic second CT scanning of the patients who died
soon after the index stroke is a limitation of the study. Those
with only a single CT scan had significantly higher mortality
(79.4% versus 20.6%) than those with several CT scans. This
is likely to result in underestimation of the frequency of
hematoma expansion in the cohort. Also, the delay between
symptom onset and the first CT scan was rather crudely
estimated. The use of 10 mm CT sections in the supratentorial
region introduces a degree of measurement error. On the
other hand, the imaging protocol was the same in all primary
and repeat scans, which are thus comparable. We did not
record occasional use of aspirin, which is another limitation.
Consequently, some patients classified as nonusers of aspirin/
warfarin may have ingested aspirin just before the stroke,
which may have worsened their outcome. Such misclassifi-
cation might underestimate aspirin-associated mortality.
In conclusion, aspirin doubled the 3-month mortality of
ICH patients compared with nonusers of aspirin/warfarin.
Aspirin-use also associated with early hematoma growth. The
observations allow us to hypothesize that aspirin-use may
predispose to hematoma enlargement. Whether the benefits
of interventions such as platelet transfusion outweigh the
risks in aspirin-associated ICH requires further study.
Acknowledgments
The study was supported in part by the Neurology Foundation,
Finland (P.S.).
References
1. Fogelholm R, Murros K, Rissanen A, Avikainen S. Admission blood
glucose and short term survival in primary intracerebral haemorrhage: a
population based study. J Neurol Neurosurg Psychiatry. 2005;76:
349–353.
2. Franke CL, van Swieten JC, Algra A, van Gijn J. Prognostic factors in
patients with intracerebral hematoma. J Neurol Neurosurg Psychiatry.
1992;55:653–657.
3. Juvela S. Risk factors for impaired outcome after spontaneous intracere-
bral hemorrhage. Arch Neurol. 1995;52:1193–1200.
4. Inagawa T, Shibukawa M, Inokuchi F, Tokuda Y, Okada Y, Okada K.
Primary intracerebral and aneurysmal subarachnoid hemorrhage in Izumo
City, Japan. Part II: Management and surgical outcome. J Neurosurg.
2000;93:967–975.
5. Tuhrim S, Dambrosia JM, Price TR, Mohr JP, Wolf PA, Hier DB, Kase
CS. Intracerebral haemorrhage: external validation and extension of a
model for prediction of 30-day survival. Ann Neurol. 1991;29:658–663.
6. Willmot M, Leonardi-Bee J, Bath PMW. High blood pressure in acute
stroke and subsequent outcome. A systematic review. Hypertension.
2004;43:18–24.
7. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracerebral
haemorrhage. Facts and hypotheses. Stroke. 1995;26:1471–1477.
8. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The
effect of warfarin and intensity of anticoagulation on outcome of intra-
cerebral haemorrhage. Arch Intern Med. 2004;164:880–884.
9. Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin,
haematoma expansion, and outcome of intracerebral haemorrhage. Neu-
rology. 2004;63:1059–1064.
10. Nilsson OG, Lindgren A, Brandt L, Sa¨veland H. Prediction of death in
patients with primary intracerebral hemorrhage: a prospective study of a
defined population. J Neurosurg. 2002;97:531–536.
11. Hemphill JC III, Bonovich DC, Besmertis L, Manley GT, Johnston SC.
The ICH Score. A simple, reliable grading scale for intracerebral hem-
orrhage. Stroke. 2001;32:891–897.
12. Teasdale G, Jennett B. Assessment of coma and impaired consciousness:
a practical scale. Lancet. 1974;2:81–94.
13. Jennett B, Bond M. Assessment of outcome after severe brain damage: a
practical scale. Lancet. 1975;1:480–484.
14. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of
intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day
mortality. Stroke. 1993;24:987–993.
15. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L,
Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients with
intracerebral hemorrhage. Stroke. 1997;28:1–5.
16. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Tanaka R. Multivariate
analysis of predictors of hematoma enlargement in spontaneous intrace-
rebral hemorrhage. Stroke. 1998;29:1160–1166.
17. The Swedish Aspirin Low-dose Trial Collaborative Group. Swedish
aspirin low-dose trial (SALT) of 75mg aspirin as secondary prophylaxis
after cerebrovascular ischaemic events. Lancet. 1991;338:1345–1349.
18. Saloheimo P, Juvela S, Riutta A, Pyhtinen J, Hillbom M. Thromboxane
and prostacyclin biosynthesis in patients with acute spontaneous intrace-
rebral hemorrhage. Thromb Res. 2005;115:367–373.
19. Takahashi H, Urano T, Nagai N, Takada Y, Takada A. Progressive
expansion of hypertensive intracerebral haemorrhage by coagulopathy.
Am J Haematol. 1998;59:110–114.
20. Fang H-Y, Lin C-Y, Ko W-J. Haematology and coagulation parameters
predict outcome in Taiwanese patients with spontaneous intracerebral
haemorrhage. Eur J Neurol. 2005;12:226–232.
21. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T,
Vcohen WA. Extravasation of radiographic contrast is an independent
predictor of death in primary intracerebral hemorrhage. Stroke. 1999;30:
2025–2032.
22. Olson JD. Hemostasis and hematologic conditions in intracerebral hem-
orrhage. In Kaufman HH, ed. Intracerebral hematomas. New York, NY:
Raven Press, 1993:151–162.
Saloheimo et al Aspirin Predicts Death in ICH 133
